Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
Adolescents face compounded GLP-1 eating disorder risk because ED prevalence peaks during adolescence while social media exposure is highest
The review identifies adolescents as the highest-risk population for GLP-1-induced eating disorder harm through a developmental timing mechanism. Two factors converge: (1) eating disorder prevalence peaks during adolescence, creating a large vulnerable population, and (2) adolescent social media use
GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
NEDA and ANAD jointly recommend that GLP-1 prescribing for patients with eating disorder risk factors require a tri-specialist care team: a physician versed in both GLP-1s and eating disorders, a therapist experienced with both GLP-1s and ED treatment, and a dietitian familiar with this medication c
Pre-treatment eating disorder screening is recommended by clinical reviews but not required by any professional guideline or regulatory body despite 4-7x elevated pharmacovigilance risk
This review provides detailed clinical recommendations for eating disorder risk mitigation: (1) pre-treatment screening using SCOFF questionnaire for eating disorder history, compensatory behaviors, body image, and emotion regulation; (2) ongoing monitoring of eating behaviors, mood, and suicidal id
GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population
Analysis of 2,061,901 adverse event reports through December 2024 found eating disorder signals with adjusted Reporting Odds Ratios between 4.17 and 6.80 across dulaglutide, semaglutide, and liraglutide—the highest magnitude psychiatric signal in the study. Critically, sensitivity analysis revealed
GLP-1 social media promotion for cosmetic weight loss creates a novel eating disorder onset pathway in vulnerable populations through unscreened access
The review identifies social media as a mechanism through which GLP-1 misuse reaches eating-disorder-vulnerable populations. Social media promotes GLP-1s 'for esthetic purposes' as miracle weight-loss treatments, which could trigger restrictive eating behaviors in vulnerable individuals. This create
No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
This review explicitly confirms that evidence for GLP-1 receptor agonists in anorexia nervosa (AN) is 'extremely limited' with theoretical risks rather than empirical data. The paper states that risks for restrictive eating disorders include 'appetite suppression masking restrictive behaviors, compu
Semaglutide reduces depression worsening by 44 percent in patients with pre-existing depression through GLP-1R-mediated psychiatric protective effects
A Swedish national cohort study of 95,490 adults with diagnosed depression, anxiety, or both found semaglutide associated with 44% lower risk of worsening depression (aHR 0.56) and 38% lower risk of worsening anxiety compared to other antidiabetic medications. The study used an active-comparator des
GLP-1 receptor agonists reduce alcohol use disorder risk by 28-36 percent across diverse populations as demonstrated by meta-analysis of 5.26 million patients
A systematic review and meta-analysis published in eClinicalMedicine synthesized 14 studies (4 RCTs and 10 observational studies) encompassing 5.26 million patients to assess GLP-1 receptor agonist effects on alcohol consumption. The analysis found three convergent signals: (1) AUDIT score reduction
Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in comorbid obesity population extending GLP-1 therapeutic scope from metabolic to behavioral health
The SEMALCO trial (N=108, 26 weeks, double-blind RCT) demonstrated semaglutide 2.4mg weekly reduced heavy drinking days by 41.1% from baseline (95% CI −48.7 to −33.5) versus 26.4% for placebo (−34.1 to −18.6), yielding a treatment difference of −13.7 percentage points (p=0.0015). This translates to
GLP-1 psychiatric effects are directionally opposite in metabolic versus psychiatric disease patients — protective in metabolic cohorts but potentially harmful in severe psychiatric comorbidity with concurrent psychotropic use
The GLP-1 psychiatric safety paradox resolves through population stratification rather than dismissing either signal. Clinical trials and cohort studies systematically exclude patients with 'psychiatric instability' — specifically those with substance use disorders, prior mood episodes, or active an
Employer GLP-1 cash-pay models separate behavioral program costs from medication costs enabling employers to fund support infrastructure without direct drug benefit exposure
Omada Health's GLP-1 Flex Care represents a structural financial innovation in response to the documented employer covered lives decline (3.6M to 2.8M). The model unbundles the behavioral program cost from medication cost: employers pay for clinical evaluation, prescribing, medical oversight, and be
GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
A 26-week randomized, double-blind, placebo-controlled trial of 108 patients with both alcohol use disorder and obesity found that weekly semaglutide plus standard cognitive behavioral therapy produced a 41.1% reduction in heavy drinking days, with 13.7% greater improvement than placebo. The number
Behavioral GLP-1 companion programs achieve 0.8 percent average weight change at one year post-discontinuation versus 11-12 percent regain in clinical trials proving standalone behavioral value
Omada Health reports that members who discontinued GLP-1 receptor agonists but continued behavioral support showed 0.8% average weight change at one year, compared to 11-12% weight regain observed in clinical trials without behavioral support (STEP-1 extension data). This 10-14x difference in post-d
AI productivity gains enable GDP-healthspan decoupling because gains are concentrated in information services and professional activities while chronic disease burden concentrates in manufacturing construction and lower-skill services
The Kansas City Fed found that productivity gains in the gen-AI era are 'MORE CONCENTRATED than the pre-pandemic era' with a distribution curve that 'stays below zero for much of the distribution and then climbs sharply near the right tail.' Gains 'appear driven by specific slices of information ser
Illinois's enforcement of the paused 2024 MHPAEA Final Rule creates a natural experiment for whether outcome data evaluation can change insurer reimbursement practices for mental health providers
On May 15, 2025, HHS announced it would not enforce amendments to MHPAEA regulations from the 2024 Final Rule, specifically the outcome data evaluation requirements designed to detect reimbursement rate discrimination. HHS encouraged but did not require states to adopt the same non-enforcement appro
Colorado HB 25-1002 establishes the first state-level outcomes data testing authority for behavioral health parity enforcement, creating a potential natural experiment for access-metric enforcement
Colorado HB 25-1002, effective January 1, 2026, grants the Insurance Commissioner explicit authority to promulgate rules establishing 'parity data testing using outcomes data' and 'documented access timelines for follow-up visits after an initial behavioral health encounter.' This is categorically d
The Mental Health Parity Index documents that 43 states have structural access disparities in commercial insurance driven by below-Medicare reimbursement rates, not just coverage design failures
The Mental Health Parity Index launched nationally on April 14, 2026, documenting that 43 of 50 states show structural disparities in access to in-network mental health and substance use disorder treatment relative to physical health care. The Index's key methodological contribution is benchmarking
AI labor market displacement is accelerating entry-level job loss in exposed occupations without reaching the physically-demanding sectors where chronic disease burden is most concentrated
Anthropic's 'observed exposure' methodology using real-world Claude usage data reveals that AI displacement follows a distinct pattern: it affects entry into the labor force rather than exit of existing workers. Brynjolfsson et al. 2025 found 6-16% employment decline among workers aged 22-25 in expo
AI produces skill compression within firms rather than across sectors, reducing performance gaps among existing workers without addressing inter-sectoral health disparities
Anthropic's synthesis of AI productivity studies reveals a consistent pattern: 'gains appear repeatedly across firms, occupations, and experimental designs and are strongest among initially lower-performing workers, producing skill compression.' This finding is critical for understanding AI's health
Reimbursement benchmarking tools are the necessary but missing infrastructure for outcome-based MHPAEA enforcement
The Mental Health Parity Index provides the first national tool that enables state regulators to measure mental health network adequacy outcomes through reimbursement rate benchmarking against Medicare payment rates. Illinois piloted the Index after signing a mental health parity bill into law, crea
MHPAEA enforcement has evolved to three levels — coverage design (level 1), access metrics (level 1.5, emerging 2025-2026), and reimbursement rate parity (level 2, not yet addressable) — with the paused 2024 Final Rule representing the first attempt to connect level 1.5 measurement to level 2 remediation
MHPAEA enforcement has historically operated at Level 1 (coverage design parity): ensuring mental health benefits exist with comparable terms to medical/surgical benefits through NQTL analysis. Traditional enforcement actions like Georgia's $25M fine and Washington state fines all operate at this le
Trump administration's MHPAEA 2024 rule enforcement pause specifically suspended outcome-data evaluation requirements while preserving procedural comparative analysis requirements that payers already know how to satisfy
On May 15, 2025, the Tri-Agencies announced non-enforcement of the 2024 MHPAEA Final Rule's new provisions, specifically targeting requirements added beyond the 2013 baseline. The 2024 rule had introduced outcome data evaluation requirements—mandating that insurers examine actual network adequacy, o
Mental health providers are reimbursed 27.1% less than medical/surgical providers for comparable services creating a structural access barrier that MHPAEA enforcement cannot address because the law requires comparable processes not comparable rates
RTI International's 2024 report documents that mental health and substance use disorder providers receive reimbursement rates 27.1% lower than medical/surgical physicians for comparable office visits. This finding was independently confirmed by The Kennedy Forum's Mental Health Parity Index for Illi
State MHPAEA enforcement addresses procedural coverage parity but cannot solve reimbursement rate disparities that drive mental health access barriers
Georgia Insurance Commissioner John F. King issued $25 million in fines across 22 major insurers (Oscar, Anthem, Kaiser, Cigna, Aetna, Humana, UnitedHealthcare, CareSource, Alliant) for mental health parity violations. This represents the largest single-state MHPAEA enforcement action in history. Vi
Two-thirds of MSSP ACOs now participate in downside risk tracks generating more than two-thirds of all savings demonstrating that the transition to full risk-bearing is accelerating despite slow aggregate payment statistics
The MSSP 2024 results reveal a critical structural shift in value-based care adoption that contradicts the narrative of stalled transition. Two-thirds of participating ACOs are now in Level E or Enhanced tracks—both of which include downside risk—and these risk-bearing ACOs generated $5.4B of the $6
Page 4 of 13